[go: up one dir, main page]

SI9200143B - Method and composition for the prevention of lyme disease - Google Patents

Method and composition for the prevention of lyme disease Download PDF

Info

Publication number
SI9200143B
SI9200143B SI9200143A SI9200143A SI9200143B SI 9200143 B SI9200143 B SI 9200143B SI 9200143 A SI9200143 A SI 9200143A SI 9200143 A SI9200143 A SI 9200143A SI 9200143 B SI9200143 B SI 9200143B
Authority
SI
Slovenia
Prior art keywords
vaccine according
polypeptide
prevention
composition
immunogen
Prior art date
Application number
SI9200143A
Other languages
English (en)
Other versions
SI9200143A (en
Inventor
Ian Livey
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9200143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of SI9200143A publication Critical patent/SI9200143A/sl
Publication of SI9200143B publication Critical patent/SI9200143B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

1 Patentni zahtevki 1. Cepivo proti lymski boreliozi, označeno s tem, da obsega imnogen iz skupine ene ali več seroloških oblik pC polipeptida B. burgdorferi v količini, ki je učinkovita za imuniziranje dovzetnega sesalca pred lymsko boreliozo, pri čemer je količina v območju od 1 do 100 pg na imunogen na dozo, in adjuvans.
2. Cepivo po zahtevku 1, označeno s tem, da obsega zmes različnih seroloških oblik ne-denaturiranega pC polipeptida.
3. Cepivo po zahtevku 1 ali 2, označeno s tem, da vsebuje enega ali več antigenov ne-pC B. burgdorferi.
4. Cepivo po zahtevkih 1 do 3, označeno s tem, daje adjuvans aluminijev hidroksid.
5. Cepivo po kateremkoli od prejšnjih zahtevkov 1 do 4, označeno s tem, da je količina v območju od 10 do 50 pg na imunogen na dozo.
6. Cepivo po kateremkoli od prejšnjih zahtevkov 1 do 5, označeno s tem, daje sesalec človek.
7. Cepivo po kateremkoli od prejšnjih zahtevkov 1 do 6, označeno s tem, da je imunogen v homogeni obliki in obsega vsaj 80 m/v% strukturno intaktnega pC polipeptida.
SI9200143A 1991-07-11 1992-07-10 Method and composition for the prevention of lyme disease SI9200143B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72724591A 1991-07-11 1991-07-11
US82416192A 1992-01-22 1992-01-22
US07/903,580 US6221363B1 (en) 1991-07-11 1992-06-25 Vaccine for the prevention of lyme disease

Publications (2)

Publication Number Publication Date
SI9200143A SI9200143A (en) 1993-03-31
SI9200143B true SI9200143B (en) 2001-06-30

Family

ID=27419096

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9200143A SI9200143B (en) 1991-07-11 1992-07-10 Method and composition for the prevention of lyme disease

Country Status (17)

Country Link
US (2) US6221363B1 (sl)
EP (1) EP0522560B2 (sl)
JP (1) JP2611095B2 (sl)
AT (1) ATE198489T1 (sl)
AU (1) AU660178B2 (sl)
CA (1) CA2073486C (sl)
CZ (1) CZ280743B6 (sl)
DE (1) DE69231619T3 (sl)
DK (1) DK0522560T4 (sl)
ES (1) ES2154633T3 (sl)
FI (1) FI107334B (sl)
HR (1) HRP950174B1 (sl)
HU (1) HU219772B (sl)
MX (1) MX9204078A (sl)
NO (1) NO304546B1 (sl)
SI (1) SI9200143B (sl)
SK (1) SK279250B6 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
ATE162550T1 (de) * 1993-04-29 1998-02-15 Immuno Ag Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995027504A1 (en) 1994-04-11 1995-10-19 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
CN1285608C (zh) * 1995-09-22 2006-11-22 康诺特实验室有限公司 副流感病毒糖蛋白和疫苗
WO1997015600A1 (en) * 1995-10-26 1997-05-01 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Tick (ixodes scapularis) vector saliva-induced lyme disease spirochete (borrelia burgdorferi) antigens as vaccine candidates
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
CA2365424A1 (en) * 1999-04-21 2000-10-26 Boston Medical Center Corporation Prevention, diagnosis and treatment of lyme disease
EP1194559B1 (en) 1999-06-18 2006-09-20 Research Foundation Of State University Of New York Groups of borrelia burgdorferi that cause lyme disease in humans
ATE381575T1 (de) 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
US8277852B2 (en) 2002-01-25 2012-10-02 Akzo Nobel Surface Chemistry Llc Bioactive botanical cosmetic compositions and processes for their production
US7442391B2 (en) 2002-01-25 2008-10-28 Integrated Botanical Technologies, Llc Bioactive botanical cosmetic compositions and processes for their production
EP1722805B1 (en) * 2004-01-12 2014-03-26 Akzo Nobel Surface Chemistry LLC Bioactive compositions from theacea plants and processes for their production and use
WO2007083834A1 (ja) 2006-01-19 2007-07-26 Toyo Seikan Kaisha, Ltd. カップラーおよび燃料電池用の燃料カートリッジ
CA2668405C (en) * 2006-11-03 2015-05-05 Schering-Plough Ltd. Canine lyme disease vaccine
AU2008217189B2 (en) * 2007-02-22 2013-06-13 Baxalta GmbH Method of purification of hydrophobic proteins
EP2274616A1 (en) * 2008-04-22 2011-01-19 The Research Foundation of State University of New York Borrelia burgdorferi cell envelope protein array
AU2010322085B2 (en) * 2009-11-17 2016-09-15 Zoetis Services Llc Peptides and methods for the detection of Lyme disease antibodies
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
KR102451333B1 (ko) * 2018-10-22 2022-10-06 주식회사 엘지화학 마이크로비드 및 그 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4767622A (en) * 1983-08-19 1988-08-30 University Of Illinois Method and materials for development of immunological responses protective against malarial infection
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
DE3818013A1 (de) 1988-05-27 1989-11-30 Henkel Kgaa Gewebeweichmachungsmittel
IT1223777B (it) * 1988-08-18 1990-09-29 Gevipi Ag Rubinetto a due uscite con inversore a depressione
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
DE3942728C1 (en) 1989-12-22 1991-05-23 Mikrogen Molekularbiologische Entwicklungs-Gmbh, 8000 Muenchen, De New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections
WO1991009870A1 (de) * 1989-12-22 1991-07-11 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff
JPH05501113A (ja) 1990-03-05 1993-03-04 アメリカ合衆国 ボレリア　ブルグドルフェリの抗原性タンパク質
IE20010565A1 (en) * 1990-07-06 2002-07-10 Wyeth Corp Vaccine Against Lyme Disease and A Challenge Model for Evaluating Vaccine Efficiency

Also Published As

Publication number Publication date
HRP950174A2 (en) 1997-08-31
US5530103A (en) 1996-06-25
AU660178B2 (en) 1995-06-15
AU1934992A (en) 1993-01-14
EP0522560B1 (en) 2001-01-03
DK0522560T4 (da) 2007-04-10
MX9204078A (es) 1993-04-01
SK217292A3 (en) 1998-08-05
HU219772B (hu) 2001-07-30
HRP950174B1 (en) 2001-08-31
EP0522560A3 (en) 1994-05-11
EP0522560B2 (en) 2006-12-20
CA2073486C (en) 2002-07-02
SK279250B6 (sk) 1998-08-05
DE69231619D1 (de) 2001-02-08
FI923175L (fi) 1993-01-12
ES2154633T3 (es) 2001-04-16
NO922746D0 (no) 1992-07-10
JPH072696A (ja) 1995-01-06
CZ217292A3 (en) 1993-01-13
CA2073486A1 (en) 1993-01-12
DK0522560T3 (da) 2001-03-05
NO304546B1 (no) 1999-01-11
FI107334B (fi) 2001-07-13
JP2611095B2 (ja) 1997-05-21
NO922746L (no) 1993-01-12
DE69231619T2 (de) 2001-05-31
FI923175A0 (fi) 1992-07-09
DE69231619T3 (de) 2007-07-12
HU9202289D0 (en) 1992-10-28
EP0522560A2 (en) 1993-01-13
HUT66525A (en) 1994-12-28
US6221363B1 (en) 2001-04-24
ATE198489T1 (de) 2001-01-15
SI9200143A (en) 1993-03-31
CZ280743B6 (cs) 1996-04-17

Similar Documents

Publication Publication Date Title
SI9200143B (en) Method and composition for the prevention of lyme disease
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
IL102639A (en) Compositions for inducing cytotoxic t lymphocyte responses
ES2109685T3 (es) Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
CA2218619A1 (en) Antibacterial-wound healing compositions and methods for preparing and using same
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
ATE100484T1 (de) Lagerstabile aufhellerformulierung.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
SE9102249D0 (sv) Framstaellningsfoerfarande foer kompositioner med foerdroejd frisaettning och de saa erhaallna kompositionerna
MX9203667A (es) Sales de bis-dimetoximetil (trimetoxibencil)quinolino, su preparacion y composicines farmaceuticas que las contienen.
AU633714B2 (en) New uses of l-deprenyl and compositions for same
ES2042153T3 (es) Agentes para el tratamiento de estados de dolor graves y procedimientopara su preparacion.
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
GR3017267T3 (en) Antiacid compositions with prolonged gastric residence time.
IL106968A0 (en) Potentiation of immunogenic response
CA2093513A1 (en) Methods and compositions for suppressing allograft rejection in mammals
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
DE69706825D1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
DK0506772T3 (da) Farmaceutisk præparat indeholdende et phosphosukker
CA2078605A1 (en) Chicken anaemia agent vaccine
ATE93388T1 (de) Paracetamol enthaltende arzneizubereitung.
IT1285779B1 (it) Composizioni miste costituite da idrotalcite e da idrossido di calcio e da idrossidi di calcio e di alluminio
RU93058633A (ru) Противоядие, способ его получения, фармацевтическая композиция, способ противодействия яду и комплект
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
ES526556A0 (es) Procedimiento para la preparacion de nuevas piridobenzodiazepinonas

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20050408